1.
Nature
; 2023 Jun 09.
Article
in English
| MEDLINE | ID: covidwho-20238146
2.
Nature
; 617(7961): 449, 2023 May.
Article
in English
| MEDLINE | ID: covidwho-2316231
Subject(s)
Biomedical Research , COVID-19 , Coronavirus , Financing, Organized , National Institutes of Health (U.S.) , Humans , Biomedical Research/economics , Biomedical Research/legislation & jurisprudence , Biomedical Research/trends , COVID-19/epidemiology , COVID-19/transmission , COVID-19/virology , National Institutes of Health (U.S.)/economics , National Institutes of Health (U.S.)/legislation & jurisprudence , Politics , United States , Viral Zoonoses/epidemiology , Viral Zoonoses/transmission , Viral Zoonoses/virology , Animals
3.
Nature
; 616(7958): 638-639, 2023 Apr.
Article
in English
| MEDLINE | ID: covidwho-2298172
4.
Nature
; 616(7958): 636-637, 2023 Apr.
Article
in English
| MEDLINE | ID: covidwho-2298171
5.
Nature
; 615(7953):572-573, 2023.
Article
in English
| ProQuest Central | ID: covidwho-2267166
ABSTRACT
In particular, the National Science Foundation (NSF) would see its budget increase by nearly 19%, and the Department of Energy's Office of Science - a big investor in the physical sciences - would see an increase of nearly 9% (see 'Biden's budget requests for science in 2024'). "The public-health system has been so underfunded for so long that the truth of the matter is, it's going to take a fair amount of money to make that right, but it's a step in the right direction," he says. Furthermore, the budget would provide $24 billion to help US communities prepare for the rising impacts of climate change, and another $7 billion to help communities that depend on oil, gas and coal extraction to tran-sition to clean energy.
6.
Nature
; 616(7956): 225-226, 2023 Apr.
Article
in English
| MEDLINE | ID: covidwho-2268607
Subject(s)
COVID-19 , Research Personnel , SARS-CoV-2 , Supermarkets , Viral Zoonoses , Humans , COVID-19/epidemiology , COVID-19/transmission , COVID-19/veterinary , COVID-19/virology , SARS-CoV-2/genetics , SARS-CoV-2/isolation & purification , China/epidemiology , Viral Zoonoses/epidemiology , Viral Zoonoses/transmission , Viral Zoonoses/virology , Animals
7.
Nature
; 2023 Jan 27.
Article
in English
| MEDLINE | ID: covidwho-2221785
8.
Nature
; 613(7943): 224-225, 2023 01.
Article
in English
| MEDLINE | ID: covidwho-2185705
9.
Nature
; 612(7941): 599, 2022 12.
Article
in English
| MEDLINE | ID: covidwho-2160178
Subject(s)
COVID-19 , Internationality , Social Media , Humans , COVID-19/epidemiology , COVID-19/prevention & control
10.
Nature
; 611(7936): 439, 2022 11.
Article
in English
| MEDLINE | ID: covidwho-2133272
11.
Nature
; 2022 Oct 31.
Article
in English
| MEDLINE | ID: covidwho-2096647
12.
Nature
; 609(7925): 17-18, 2022 09.
Article
in English
| MEDLINE | ID: covidwho-2000863
13.
Nature
; 605(7908): 22-24, 2022 05.
Article
in English
| MEDLINE | ID: covidwho-1830016
14.
Nature
; 604(7905): 230-231, 2022 04.
Article
in English
| MEDLINE | ID: covidwho-1795827
Subject(s)
Brain , Organ Size , Brain/anatomy & histology , Brain/growth & development , Humans , Time Factors
15.
Nature
; 604(7904): 18-19, 2022 04.
Article
in English
| MEDLINE | ID: covidwho-1783953
16.
Nature
; 2022 Feb 04.
Article
in English
| MEDLINE | ID: covidwho-1669051
17.
Nature
; 601(7894): 491-493, 2022 Jan.
Article
in English
| MEDLINE | ID: covidwho-1661950
18.
Nature
; 601(7894): 496, 2022 01.
Article
in English
| MEDLINE | ID: covidwho-1641925
Subject(s)
Antiviral Agents/therapeutic use , COVID-19 Drug Treatment , COVID-19/virology , Drug Development/trends , Drug Resistance, Viral , Research Personnel , SARS-CoV-2/drug effects , Adenosine Monophosphate/administration & dosage , Adenosine Monophosphate/analogs & derivatives , Adenosine Monophosphate/pharmacology , Adenosine Monophosphate/therapeutic use , Administration, Oral , Alanine/administration & dosage , Alanine/analogs & derivatives , Alanine/pharmacology , Alanine/therapeutic use , Antiviral Agents/administration & dosage , Antiviral Agents/pharmacology , Antiviral Agents/supply & distribution , COVID-19/mortality , COVID-19/prevention & control , COVID-19 Vaccines/supply & distribution , Cytidine/administration & dosage , Cytidine/analogs & derivatives , Cytidine/pharmacology , Cytidine/therapeutic use , Drug Approval , Drug Combinations , Drug Resistance, Viral/drug effects , Drug Resistance, Viral/genetics , Drug Therapy, Combination , Hospitalization/statistics & numerical data , Humans , Hydroxylamines/administration & dosage , Hydroxylamines/pharmacology , Hydroxylamines/therapeutic use , Lactams/administration & dosage , Lactams/pharmacology , Lactams/therapeutic use , Leucine/administration & dosage , Leucine/pharmacology , Leucine/therapeutic use , Medication Adherence , Molecular Targeted Therapy , Mutagenesis , Nitriles/administration & dosage , Nitriles/pharmacology , Nitriles/therapeutic use , Proline/administration & dosage , Proline/pharmacology , Proline/therapeutic use , Public-Private Sector Partnerships/economics , Ritonavir/administration & dosage , Ritonavir/pharmacology , Ritonavir/therapeutic use , SARS-CoV-2/enzymology , SARS-CoV-2/genetics
19.
Nature
; 2022 Jan 19.
Article
in English
| MEDLINE | ID: covidwho-1628765
20.
Nature
; 601(7892): 177, 2022 01.
Article
in English
| MEDLINE | ID: covidwho-1602941